Sage Therapeutics Inc (NAS:SAGE)
$ 11.09 0.46 (4.31%) Market Cap: 669.82 Mil Enterprise Value: -72.17 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 46/100

SAGE Therapeutics Inc at Cowen HealthCare Conference Transcript

Mar 02, 2020 / 05:00PM GMT
Release Date Price: $53.36 (+13.53%)
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Thank you, everyone, for joining us here at the Cowen Health Care Conference and the Sage Therapeutics fireside chat. With us today for the conversation, we have SVP of Clinical Development, Chris Silber; Mike Cloonan, Chief Business Officer; and Kimi Iguchi, CFO. I will turn it over to Kimi for a few opening remarks, and then we'll jump into the Q&A.

Kimi E. Iguchi
Sage Therapeutics, Inc. - CFO & Treasurer

Great. Well, thank you, Ritu. Thanks very much for -- we're delighted to be here. Again, my name is Kimi Iguchi. I'm the Chief Financial Officer. And just to start, a little housekeeping, we will be making forward-looking statements. So you can certainly access our SEC filings on our website. But just for those of you who might not be as familiar with Sage, we were -- we're about 9 years old. And when we started, it was really all about brain disorders and thinking about how we can help people with brain disorders. And at the time we've started

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot